← Back to Screener
Femasys Inc. Common Stock (FEMY)
Price$0.42
Favorite Metrics
Price vs S&P 500 (26W)-32.14%
Price vs S&P 500 (4W)-34.32%
Market Capitalization$25.91M
All Metrics
Book Value / Share (Quarterly)$0.10
P/TBV (Annual)5.98x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)23.75%
Cash Flow / Share (Quarterly)$-0.32
Price vs S&P 500 (YTD)-28.19%
Gross Margin (TTM)61.96%
Net Profit Margin (TTM)-812.27%
EPS (TTM)$-0.56
10-Day Avg Trading Volume0.39M
EPS Excl Extra (TTM)$-0.56
Revenue Growth (5Y)17.13%
EPS (Annual)$-0.47
ROI (Annual)-205.87%
Gross Margin (Annual)61.96%
Net Profit Margin (5Y Avg)-975.33%
Cash / Share (Quarterly)$0.16
Revenue Growth QoQ (YoY)39.86%
ROA (Last FY)-89.88%
Revenue Growth TTM (YoY)40.77%
EBITD / Share (TTM)$-0.42
ROE (5Y Avg)-262.99%
Operating Margin (TTM)-766.96%
Cash Flow / Share (Annual)$-0.32
P/B Ratio4.41x
P/B Ratio (Quarterly)5.84x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)8.64x
Net Interest Coverage (TTM)-9.41x
ROA (TTM)-116.29%
EPS Incl Extra (Annual)$-0.47
Current Ratio (Annual)4.53x
Quick Ratio (Quarterly)2.95x
3-Month Avg Trading Volume0.89M
52-Week Price Return-62.37%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.10
P/S Ratio (Annual)11.30x
Asset Turnover (Annual)0.11x
52-Week High$1.29
Operating Margin (5Y Avg)-975.52%
EPS Excl Extra (Annual)$-0.47
CapEx CAGR (5Y)83.85%
26-Week Price Return-28.15%
Quick Ratio (Annual)2.95x
13-Week Price Return-27.87%
Total Debt / Equity (Annual)0.54x
Current Ratio (Quarterly)4.53x
Enterprise Value$19.82
Revenue / Share Growth (5Y)-8.08%
Asset Turnover (TTM)0.14x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.20x
Pretax Margin (Annual)-812.21%
Cash / Share (Annual)$0.16
3-Month Return Std Dev87.13%
Gross Margin (5Y Avg)64.90%
Net Income / Employee (TTM)$-0
ROE (Last FY)-317.38%
Net Interest Coverage (Annual)-9.41x
EPS Basic Excl Extra (Annual)$-0.47
Receivables Turnover (TTM)4.15x
Total Debt / Equity (Quarterly)0.54x
EPS Incl Extra (TTM)$-0.56
Receivables Turnover (Annual)4.15x
ROI (TTM)-208.50%
P/S Ratio (TTM)11.30x
Pretax Margin (5Y Avg)-974.95%
Revenue / Share (Annual)$0.06
Tangible BV / Share (Annual)$0.10
Price vs S&P 500 (52W)-92.20%
Year-to-Date Return-25.55%
5-Day Price Return8.55%
EPS Normalized (Annual)$-0.47
ROA (5Y Avg)-77.24%
Net Profit Margin (Annual)-812.27%
Month-to-Date Return2.09%
Cash Flow / Share (TTM)$-0.94
EBITD / Share (Annual)$-0.42
Operating Margin (Annual)-766.96%
LT Debt / Equity (Annual)0.54x
ROI (5Y Avg)-122.54%
LT Debt / Equity (Quarterly)0.54x
EPS Basic Excl Extra (TTM)$-0.56
P/TBV (Quarterly)5.98x
P/B Ratio (Annual)5.84x
Inventory Turnover (TTM)0.20x
Pretax Margin (TTM)-812.21%
Book Value / Share (Annual)$0.10
Price vs S&P 500 (13W)-28.56%
Beta-2.29x
Revenue / Share (TTM)$0.04
ROE (TTM)-534.91%
52-Week Low$0.31
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.11
4.11
4.11
4.10
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
FEMYFemasys Inc. Common Stock | 11.30x | 17.13% | 61.96% | -766.96% | $0.42 |
SYKStryker Corporation | 5.15x | 11.84% | 64.57% | 19.43% | $338.38 |
BSXBoston Scientific Corp. | 4.76x | 15.16% | 69.01% | 18.00% | $63.42 |
MMM3M Company | 3.18x | -4.97% | 39.92% | 18.55% | $150.55 |
MDLNMedline Inc. Class A common stock | 2.21x | — | 26.44% | 7.78% | $46.94 |
BDXBecton, Dickinson and Co. | 2.01x | 6.32% | 46.42% | 12.15% | $154.82 |
RMDResMed Inc. | 6.06x | 11.72% | 60.85% | 33.70% | $224.72 |
DXCMDexCom, Inc. | 5.23x | 19.33% | 62.09% | 19.56% | $61.23 |
WSTWest Pharmaceutical Services, Inc. | 6.22x | 7.44% | 35.91% | 19.03% | $269.81 |
PODDInsulet Corporation | 5.31x | 24.53% | 71.63% | 12.92% | $201.47 |
PENPenumbra, Inc. | 9.31x | 20.16% | 67.14% | 13.48% | $331.47 |
About
Femasys develops minimally invasive medical devices for women's healthcare, offering office-based solutions for infertility treatment, contraception, and diagnostic procedures. Its product portfolio includes FemaSeed for intratubal insemination, FemVue for fallopian tube assessment, FemBloc for permanent contraception (in development), FemCerv for cervical cancer diagnosis, and FemCath and FemChec. The company generates revenue primarily from the United States market with additional international sales.